Discovery & Preclinical Development was Evotec SE’s largest segment in fiscal 2025, bringing in $528.93M of $788.37M (67%).
| Segments [axis] | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Discovery & Preclinical Development | — | $672.98M | $611.39M | $528.93M | |||
| Shared Rd | $702.02M | — | — | — | |||
| Evt Execute | — | — | — | — | |||
| Just - Evotec Biologics | $49.43M | $108.45M | $185.57M | $259.44M | |||
| Evt Innovate | — | — | — | — | |||
| Intersegment Eliminations | — | — | — | — | |||
| Total | $751.45M | $781.43M | $796.97M | $788.37M |
Evotec SE brought in $788.37M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 1.1% from $796.97M in fiscal 2024. Discovery & Preclinical Development was the largest at $528.93M (67.1%), ahead of Just - Evotec Biologics at $259.44M (32.9%).
Compared with fiscal 2024, Just - Evotec Biologics grew 39.8% to $259.44M, while Discovery & Preclinical Development fell 13.5% to $528.93M.
Evotec SE began breaking out Discovery & Preclinical Development in fiscal 2023, when it brought in $672.98M. Evotec SE stopped reporting Shared Rd as a separate segment after fiscal 2022, when it brought in $702.02M.
United States was Evotec SE’s largest region in fiscal 2020, bringing in $247.85M of $500.92M (49%).
| Geography | FY 2019 | FY 2020 |
|---|---|---|
| United States | — | $247.85M |
| Usa | $195.04M | — |
| United Kingdom | $77.90M | $93.99M |
| Rest Of The World | $82.68M | $77.71M |
| France | $62.83M | $37.06M |
| Germany | $27.98M | $44.32M |
| Total | $446.44M | $500.92M |
Evotec SE brought in $500.92M from its five regions in fiscal 2020, the year ended December 31, 2020. Evotec SE regrouped these regions after fiscal 2019, so the total does not compare directly with that year's $446.44M. United States was the largest at $247.85M (49.5%), ahead of United Kingdom at $93.99M (18.8%) and Rest Of The World at $77.71M (15.5%). The other two regions brought in $81.38M combined.
Compared with fiscal 2019, Germany grew fastest, up 58.4% to $44.32M, while France fell the most, down 41.0% to $37.06M.
Evotec SE began breaking out United States in fiscal 2020, when it brought in $247.85M. Evotec SE stopped reporting Usa as a separate region after fiscal 2019, when it brought in $195.04M.
Service Fees & Fte-Based Research Payments was Evotec SE’s largest revenue line in fiscal 2020, bringing in $460.59M of $505.57M (91%).
| Products and services [axis] | FY 2019 | FY 2020 |
|---|---|---|
| Service Fees & Fte-Based Research Payments | $398.58M | $460.59M |
| Milestone Fees | $30.44M | $17.09M |
| Material Recharges | — | $21.84M |
| Recharges | $14.50M | — |
| Contributions | $4.55M | $4.65M |
| Compound Access Fees | $1.02M | $1.36M |
| Licences | $1.90M | $42.00K |
| Total | $450.98M | $505.57M |
Evotec SE brought in $505.57M from its six revenue lines in fiscal 2020, the year ended December 31, 2020. Evotec SE regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $450.98M. Service Fees & Fte-Based Research Payments was the largest at $460.59M (91.1%), ahead of Material Recharges at $21.84M (4.3%) and Milestone Fees at $17.09M (3.4%). The other three revenue lines brought in $6.05M combined.
Compared with fiscal 2019, Service Fees & Fte-Based Research Payments grew 15.6% to $460.59M, while Milestone Fees fell 43.8% to $17.09M.
Evotec SE began breaking out Material Recharges in fiscal 2020, when it brought in $21.84M. Evotec SE stopped reporting Recharges as a separate revenue line after fiscal 2019, when it brought in $14.50M.
Evotec SE (EVO) reports its revenue by segments [axis], by geography and by products and services [axis]. In fiscal 2025, Discovery & Preclinical Development was its largest segment, bringing in $528.93M (67.1% of the total), followed by Just - Evotec Biologics at $259.44M (32.9%).
Discovery & Preclinical Development was Evotec SE's largest segment in fiscal 2025, bringing in $528.93M, or 67.1% of the $788.37M total across its two segments.
United States was Evotec SE's largest region in fiscal 2020, bringing in $247.85M, or 49.5% of the $500.92M total across its five regions.
Service Fees & Fte-Based Research Payments was Evotec SE's largest revenue line in fiscal 2020, bringing in $460.59M, or 91.1% of the $505.57M total across its six revenue lines.
Just - Evotec Biologics grew faster than Discovery & Preclinical Development in fiscal 2025, up 39.8% from $185.57M to $259.44M. Discovery & Preclinical Development fell 13.5% to $528.93M.
Every figure comes from Evotec SE's annual financial filings, as reported. Each line keeps the name Evotec SE gives it, and years follow its fiscal calendar.
Evotec SE's revenue by segments [axis] goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.